TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
JNJ

Johnson & Johnson

Healthcare · Drug Manufacturers - General

261.40$ +1.9% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Cash Flow

Johnson & Johnson (JNJ) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 4,711 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow JNJ
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
5,361 6,653 2,913 5,772 6,266 6,105 3,606 6,079 6,272 6,244 3,543 5,948 7,527 6,398 3,358 3,452 8,383 8,343 4,074 5,314 8,290 5,732 3,979 5,581 6,284 5,350 3,257 4,182 7,489 7,863 3,657 5,633 7,993 6,983 4,174 3,878 9,169 7,309 2,514 4,711 23,703
908 1,055 912 1,150 1,711 1,869 1,746 1,717 1,731 1,735 1,761 1,705 1,727 1,816 1,747 1,726 1,818 1,940 1,894 1,839 1,814 1,843 1,769 1,744 1,685 1,772 1,880 1,934 1,829 1,843 1,815 1,782 1,846 1,896 1,772 1,943 1,777 2,011 2,004 1,959 7,751
225 174 229 293 236 204 268 312 242 156 258 314 245 160 263 326 256 160 307 354 259 215 278 366 281 213 306 382 296 178 302 341 295 238 288 410 347 309 300 458 1,414
228 -574 226 465 -499 2,681 292 -429 1,792 -1,683 734 -1,945 -1,219 -147 -633 -99 403 -770 -1,002 351 -690 1,341 -200 -974 171 1,297 -818 – – – – – – – – – – – – – –
-47 2,358 -2,647 330 1,290 12,268 -2,799 837 -1,185 3,150 -2,701 581 5,266 719 -3,552 -1,801 2,608 5,435 -3,015 -3,154 3,499 -1,568 -2,739 -3.0 -30 -1,239 2,263 -2,401 -602 3,247 -338 -452 1,829 798 -11,024 -4,921 15,945 -12,718 -5,226 1,321 -678
737 1,093 560 689 790 1,240 658 875 819 1,318 656 837 745 1,260 625 662 737 1,323 677 813 747 1,415 607 863 952 1,587 863 1,124 967 1,589 807 976 2,279 2,145 795 1,398 788 1,837 1,049 1,321 4,995
-2,372 -2,174 -936 -12,247 -1,180 -505 -925 -201 -4,269 2,228 -1,417 -1,788 -1,645 -1,344 -581 -7,522 -4,819 -7,903 -185 -419 -2,719 -5,360 -3,634 -2,639 -1,701 -4,397 3,315 -3,776 2,541 -1,202 -464 -13,687 -3,128 -1,320 -297 -18,264 -542 -4,485 -1,040 -1,110 -7,177
2,185 2,170 2,171 2,262 2,254 2,256 2,253 2,415 2,415 2,411 2,396 2,522 2,499 2,500 2,505 2,659 2,659 2,658 2,659 2,791 2,791 2,791 2,787 2,971 2,970 2,954 2,942 3,092 2,871 2,865 2,869 2,985 2,985 2,984 2,989 3,129 3,132 3,131 3,131 3,227 12,621
-2,203 -2,025 -3,342 -1,890 -311 -815 -1,444 -145 -471 -3,808 -2,206 -2,486 -1,628 -426 -1,711 -706 -483 -321 -1,438 -631 -391 -996 -1,577 -973 -2,165 -1,320 -3,537 -381 -920 -216 -1,475 -136 -539 -282 -2,127 -1,570 -1,902 -1,924 -4,028 -221 -8,075
775 654 4,986 1,918 361 -511 -2,464 52 -817 -720 -1,005 4.0 55 -1,935 -19 2,709 7,204 -2,799 -1,452 -189 654 987 31 9.0 119 7,293 12,880 -7,097 – – – – -6,431 1,535 15,051 -2,376 -5,143 2,105 7,214 -5,748 -1,572
-3,445 -3,464 -150 -1,917 -2,069 -3,537 -5,970 -2,674 -3,477 -6,389 -5,516 -4,534 -3,893 -4,072 -4,315 -357 4,196 -5,644 -5,125 -3,279 -2,207 -3,436 -4,385 -2,261 -3,925 1,700 6,138 -5,991 -11,317 -4,655 546 7,544 -9,882 -1,340 10,422 -5,665 -8,927 -1,369 530 -15,387 -25,153
-435 767 1,937 -8,311 3,123 2,103 -3,185 2,930 -1,513 2,051 -3,373 -358 1,873 1,056 -1,775 -4,356 7,791 -4,980 -1,314 1,661 3,272 -3,117 -4,024 520 372 2,772 12,738 -5,682 -1,455 2,131 3,614 -595 -4,898 4,125 14,369 -19,897 -346 1,478 1,979 -11,781 -8,670
4,624 5,560 2,353 5,083 5,476 4,865 2,948 5,204 5,453 4,926 2,887 5,111 6,782 5,138 2,733 2,790 7,646 7,020 3,397 4,501 7,543 4,317 3,372 4,718 5,332 3,763 2,394 3,058 6,522 6,274 2,850 4,657 5,714 4,838 3,379 2,480 8,381 5,472 1,465 3,390 18,708

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?